DanCann Pharma A/S: Solid growth in the Rx portfolio
COPENHAGEN, Denmark, 18 June 2024 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby provides an update on its current portfolio and expectations for the year ahead.Key highlights from the portfolio[1] and pipeline[2]: · Growth in 2023: Achieved a sales growth of +40% year-over-year (YoY) in pharmacy sales. · Sales volume: This growth equated to +14,000 packages of medicine. · 2024 projections: The Company aims to further increase the current Rx portfolio sales volume to 20,000 packages in 2024, representing a